UNSPSC 51461504: Aconitum napelus

This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers U0NQ8555JD and KPD2N7348X, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 18174 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Ranunculanae, Order Ranunculales, Family Ranunculaceae, Genus Aconitum, commonly known as MONKSHOOD or WOLFSBANE or as here, ACONITUM NAPELUS.

European Medicines Agency schedules aconitum napelus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB45854, SUB45855, SUB45856, SUB45857, SUB45858, SUB45859, SUB45860, SUB45861, and SUB49093.

UNSPSC 51461504 Aconitum napelus is a Commodity code nominally identifying a specific pharmaceutical substance, but recent state and local activity under this code shows little alignment with the narrow botanical name. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter (OTC) products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. The procurement targets manufacturers capable of supplying comprehensive product catalogs with detailed National Drug Codes (NDC), pricing across multiple net-price formats (including flat price, NF30, NF60, NF90, and WAC-minus structures), and compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). Vendors must maintain contractual relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and carry comprehensive insurance including $5 million commercial general liability and $2 million network security and privacy liability per occurrence. The code appears to show limited recent activity specifically targeting Aconitum napelus as a discrete product; instead, procurement activity reflects broad categorical pharmaceutical sourcing.

The MMCAP RFP (S1070000015802) represents the primary recent state and local opportunity under this code, with a proposal due date of March 26, 2026, and contract effectiveness set for July 1, 2026. Evaluation weighting emphasizes price competitiveness (75 percent), with smaller allocations for fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee (each 5–10 percent). The contract term runs two years for new responders with optional MMCAP extensions, while incumbents' amendments extend through June 30, 2028. No specific set-aside designations or disadvantaged-enterprise restrictions are disclosed in the solicitation materials. This code's recent activity does not support pursuit if your firm specializes in single-molecule pharmaceutical products; the MMCAP vehicle targets broad, price-competitive catalog sourcing more typical of generic pharmaceutical wholesaling than specialty actives.